Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma

Oncology Reports

Volumn 25, Issue 4, 2011, Pages 1047-1052

  Wang, Yong ^a,b   Chen, Jian ^a   Li, Xiaoqiu ^a   He, Yifu ^a   Hu, Bing ^a   Ji, Chushu ^a   Xu, Jianming ^a,b,c  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Gastroenterology of Anhui Province   (China)

^c First Affiliated Hospital   (China)

Author keywords

Advanced esophageal carcinoma; Cisplatin; Fluorouracil; Genetic polymorphisms

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; DRUG EFFICACY; DRUG MECHANISM; ESOPHAGUS CARCINOMA; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; SURVIVAL RATE;

EID: 79952228118     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1170     Document Type: Article

References (25)

1. Wei WQ, Yang J, Zhang SW, Chen WQ and Qiao YL: [Analysis of the esophageal cancer mortality in 2004-2005 and its trends during last 30 years in China]. Zhonghua Yu Fang Yi Xue Za Zhi 44: 398-402, 2010.
2. Llson DH: Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res 2: 85-92, 2008.
3. Maeda J, Hirano T, Ogiwara A, et al: Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer 98: 596-603, 2008. (Pubitemid 351214526)
4. Bernig T and Chanock SJ: Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn 6: 319-331, 2006. (Pubitemid 44174338)
5. Yuan P, Miao XP, Zhang XM, et al: [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy]. Ai Zheng 24: 1510-1513, 2005.
6. Kang S, Ju W and Kim JW: Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38: 320-324, 2006. (Pubitemid 44033245)
7. Sun N, Sun X, Chen B, Cheng H, Feng J, Cheng L and Lu Z: MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 65: 437-446, 2009.
8. Fareed KR, Al-Attar A, Soomro IN, et al: Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 102: 1600-1607, 2010.
9. Shibata Y, Baba E, Ariyama H, et al: Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin. World J Gastroenterol 13: 3634-3637, 2007. (Pubitemid 47162274)
10. Malandrino P, Al Ghuzlan A, Castaing M, et al: Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 17: 797-807, 2010.
11. Krivak TC, Darcy KM, Tian C, et al: Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 26: 3598-3606, 2008.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
13. Fujii T, Toyooka S, Ichimura K, et al: ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small cell lung cancer. Lung Cancer 59: 377-384, 2008. (Pubitemid 351335101)
14. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998. (Pubitemid 28041614)
15. Reed E, Dabholkar M, Thornton K, Thompson C, Yu JJ and Bostick-Bruton F: Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncol Rep 7: 1123-1128, 2000.
16. Wood RD: DNA repair in eukaryotes. Annu Rev Biochem 65: 135-167, 1996.
17. Vogel U, Dybdahl M, Frentz G and Nexo BA: DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 461: 197-210, 2000.
18. Chen P, Wiencke J, Aldape K, et al: Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9: 843-847, 2000. (Pubitemid 30660059)
19. Bradbury PA, Marshall AL and Kulke AH: Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 25: 2511, 2007.
20. Park DJ, Zhang W, Stoehlmacher J, et al: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1: 162-166, 2003.
21. Ryu JS, Hong YC, Han HS, et al: Association between polymorphisms of ERCC1 and XPD and survival in non-small cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44: 311-316, 2004.
22. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS and Kim HJ: Prognostic value of expression of ERCCl, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18: 504-509, 2007. (Pubitemid 46359630)
23. Ruzzo A, Graziano F, Kawakami K, et al: Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24: 1883-1891, 2006.
24. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC and Lenz HJ: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94: 936-942, 2002. (Pubitemid 34778092)
25. Yang LY, Li L, Jiang H, Shen Y and Plunkett W: Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6: 773-781, 2000. (Pubitemid 30159329)